Background and objectives: Anemia in patients with chronic kidney disease (CKD) is related
Introduction
Erythropoietin (EPO) was first isolated in 1971 1 and its gene cloned in 1985. 2 Produced in the kidney and the liver, EPO stimulates the differentiation and proliferation of erythroid progenitors. The subsequent synthesis of recombinant human erythropoietin markedly changed the management of end stage renal disease (ESRD)-related anemia. Recent findings that erythropoiesis stimulating agents (ESA) did not improve cardiovascular and renal outcomes in patients with non-end-stage chronic kidney disease (CKD) 3 4 5 have raised questions about the timing and degree of EPO deficiency in renal anemia. 6 Our knowledge of the underlying cause of impaired EPO production is also incomplete.
Decrease in the endogenous EPO response to anemia, is thought to be one of the major mechanisms of CKD anemia. In subjects without CKD, EPO and Hb levels are negatively correlated, a feedback regulation that tends to be reversed in CKD patients. 7 8 9 In ESRD patients, the feedback regulation process is blunted, even though it is somewhat preserved after hemorrhage 10 11 and possibly at high altitudes. 12 EPO levels remain in the normal range in CKD patients compared to non-anemic healthy controls. 7 13 14 But for the degree of their anemia, CKD patients had EPO level lower than expected. The decrease in the endogenous EPO response to anemia has not been quantified in CKD patients, however. In addition, all studies conducted before 1980 used bioassays that provided higher EPO levels than those measured with present double-antibody sandwich immunoassays. Moreover, although inflammation and iron deprivation are well-documented risk factors for ESA resistance in dialysis patients, the determinants of EPO production have not been systematically studied in early-stage CKD.
We therefore used reference methods to investigate the timing of EPO deficiency and its determinants according to renal function in 336 CKD patients. In those with anemia, we also quantified the endogenous EPO response to Hb decreases according to GFR level.
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Methods
Study population
The Nephrotest study is a prospective hospital-based cohort, enrolling adult patients with all CKD diagnoses, stages 1 through 5, not pregnant and not on dialysis or living with a kidney transplant. 15 By the end of 2009, a total of 1294 patients had been referred to 2 physiology departments for work-ups to assess CKD progression and complications, including measured GFR (mGFR), according to standard methods. All patients provided written informed consent before inclusion in the cohort. In this study, we analyzed a subgroup of 336 patients who were receiving neither ESA nor intravenous iron and whose endogenous EPO was assayed. They did not differ from those without EPO measures for baseline age, gender, diabetes, median mGFR, or Hb level (data not shown).
Information
Demographic, clinical, and laboratory data were collected. Twenty-one percent of all patients had biopsy-proven nephropathy, but less than 10% of those with diabetes. Clinical criteria based on the presence of a history of albuminuria > 300 mg/g creatininuria and of another microangiopathy damage (retinopathy or/and neuropathy) were used to classify diabetic patients without renal biopsy as having diabetic glomerulopathy. Other diabetic patients were classified as having other nephropathy types, most of them having probably a vascular nephropathy. We used Lipschitz's index 16 to define iron status based on transferrin saturation (TSAT) and ferritin as follows: normal, TSAT ≥ 20%; TSAT < 20% and ferritin < 40 ng/mL, absolute iron deficiency; TSAT < 20% and ferritin ≥ 40 ng/mL, functional iron deficiency.
We primarily used WHO sex-specific thresholds to define anemia: Hb concentration < 12 g/dL for women and <13 g/dL for men. GFR was measured by renal clearance of 51 Cr-EDTA inserm-00739807, version 1 -9 Oct 2012
as described earlier 17 and categorized according to Kidney Disease Improving Global
Outcomes guidelines.
18
Erythropoietin measurement and responsiveness to Hb level
Endogenous EPO levels were determined in serum (100 µL) with the Quantitine IVD Epo double-antibody sandwich ELISA method from R&D Systems (Minneapolis, MN).
To assess the response of endogenous EPO to Hb levels, we used a method previously developed and validated in non-CKD patients with anemia. 19 other types of nephropathy in model 2, and iron index and CRP in model 3. We studied log 10 EPO and expressed the results in percentage of EPO change in the exposed compared with the reference category. All analyses were performed with SAS 9.1 (SAS Institute, Cary, NC). inserm-00739807, version 1 -9 Oct 2012
Results
Patient characteristics
Mean age was close to 60 years, and patients were predominantly men and of European origin (Table 1) . Vascular nephropathy was the most common type of CKD. Two thirds of the patients had CKD stage 3B or 4. WHO-defined anemia (Hb <13 (12) g/dL in men (women)) was present in 55% of men and 63% of women. EPO levels ranged from 1.9 to 47.8 IU/L. (Table 2) . EPO levels were not related to gender, geographic origin, treatment with renin angiotensin system inhibitors, or urine protein to creatinine ratio, vitamin D or folate levels. There was a significant interaction (p = 0.04) between serum albumin and mGFR:
Relations between erythropoietin, hemoglobin, and measured GFR levels
higher EPO levels with lower albumin values were observed only in patients with mGFR ≥ 30 mL/min/1.73 m². No other significant interaction was seen with mGFR, gender, or anemia (all p ≥ 0.2). Mean Hb level was significantly higher in patients overweight or obese than in those with normal BMI, 12.6 ± 1.5 g/dL vs 12.2 ± 1.3 g/dL (p=0.03), but did not significantly differ with CRP level ≤ or > 8 mg/L, 12.5 ± 1.5 g/dL vs 12.1 ± 1.5 g/dL (p=0.1).
Multivariate analysis of factors associated with change in erythropoietin levels
In view of the observed interaction between mGFR and anemia status, we created a combined variable for multivariate analyses (Table 3) . After adjusting for covariates, EPO levels were 17.3% higher in patients with WHO-defined anemia and mGFR ≥ 30 mL/min/m² than in the reference group without anemia, whereas they were similar in those with anemia and mGFR < 30 mL/min/1.73m² (Table 3 ). The fully-adjusted EPO increase was associated with overweight, obesity, diabetes with nephropathy types other than diabetic glomerulopathy, absolute iron deficiency, and CRP > 8 mg/L and ranged from 22 to 55%. Including these variables significantly improved the log likelihood of the fully-adjusted model compared to that with anemia and mGFR alone to explain EPO changes. Serum albumin and EPO levels were no longer associated after adjusting for the covariates. Similar results were obtained throughout the analysis when using a unique cut-off value of 12 g/dL for both genders. EPO level for patients with anemia and mGFR ≥ 30 mL/min/1.73m² was 13% higher than in those without anemia (p=0.04), and relations with other factors were unchanged.
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Discussion
This study confirms the existence of an interaction between hemoglobin, GFR and erythropoietin in non-end-stage CKD, but its contribution and novelty lie in four key points.
First, in contrast with earlier studies, the analysis was conducted by anemia status, which enabled to show that there was no relation between EPO concentration and mGFR levels in patients without anemia, whereas EPO deficiency increases with mGFR decline in anemic patients. Second, the most original findings indicate that several factors other than Hb and GFR levels may stimulate EPO production in CKD. Third, this study also quantified the relative EPO deficiency throughout the range of mGFR pointing out its importance as early as stages 1-2 that worsens as mGFR declines to reach 64% at stage 5. Finally, the quality of patient phenotype, both regarding GFR and EPO measurements resulted in a most accurate assessment of the EPO deficiency in non end-stage CKD.
In both normal and disease conditions, serum EPO must be interpreted according to Hb level. 8 Under non-anemic conditions, there is no need for higher EPO since Hb concentration and oxygen supply to tissues is still sufficient. In contrast, in patients with anemia, serum EPO is expected to be inversely correlated with Hb, as a result of the feedback process described in the introduction. 7 8 Impairment of this physiological feedback process in CKD was first described in dialysis patients. 7 Fehr et al. first suggested that it began below a GFR of 40 mL/min/1.73m², but did not stratified the analysis by anemia status. 9 Here, we studied the interaction between Hb and GFR according to anemia status and found a slightly lower GFR threshold in patients with anemia, at 30 mL/min/1.73m², probably explained by their use of Cockcroft-Gault estimated GFR while we used measured GFR.
We further showed that despite very early relative EPO deficiency in the course of CKD, physiological response to anemia was somewhat preserved in patients with GFR above 30 mL/min/1.73m². Conversely, below 30 mL/min/1.73m², patients with anemia had severe inserm-00739807, version 1 -9 Oct 2012 EPO deficiency, with lower EPO levels than patients without anemia. At this stage, declining EPO concentration is likely to explain a major part of CKD anemia.
Beyond Hb and mGFR levels, a number of other factors were related to EPO concentration. First, we found absolute iron deficiency was associated with an increased EPO level. This association has previously been described in non-CKD patients and in dialysis patients. 22 23 24 25 It was also expected based on recent findings about the involvement of EPO in iron metabolism and particularly about hepcidin. 26 EPO reduces circulating hepcidin in humans 27 and directly affects the intestinal handling of iron in rat models. 28 Inversely, absolute iron deficiency is associated with increased EPO levels and early blockage of erythroid differentiation. 29 Transferrin receptor 2 (TfR2), recently described as a sensor of body iron levels, may mediate EPO change with absolute iron deficiency. 30 Interestingly, diabetes with nephropathy other than diabetic glomerulopathy was associated with enhanced EPO production, while diabetic glomerulopathy was not. To the best of our knowledge, this finding is new and requires confirmation by others. In contrast, other authors 31 32 suggest that EPO response may be blunted in diabetic patients with microangiopathy, thus explaining their higher rate of anemia compared to non diabetic patients. Although we previously described such a higher rate of anemia, our findings here do not support this hypothesis, as EPO levels did not differ between patients with diabetic glomerulopathy and those without diabetes.
Another novel finding is that higher EPO levels were associated with increasing BMI.
Several studies have shown no excess risk of anemia in patients with obesity despite increased inflammation and functional iron deficiency related to the hepcidin increase. 15 33 34 We have previously described a 40% lower risk of anemia in obese patients in the NephroTest cohort. 15 This apparently protective effect of obesity on anemia may result from the positive relation we observed between BMI and EPO levels. Further research is needed to investigate whether inserm-00739807, version 1 -9 Oct 2012
sleep apnea syndrome and its consequence, the chronic hypoxia common in obese patients, is a plausible trigger for the EPO increase.
Finally, we found a positive association between inflammation and EPO level, independent of Hb and mGFR levels. Wagner et al recently found the same association in diabetic patients with CKD. 35 Experimentally, it is well established that EPO production is down-regulated by some cytokines that also influence EPO action. 36 37 38 In clinical studies, however, patients with chronic inflammation have preserved EPO feedback to changes in their Hb level. 39 40 41 Their EPO level is somewhat less stimulated than it is in the presence of absolute iron deficiency, which has the strongest impact on EPO production. Of note both EPO level was measured only once for each patient, the robustness of the correlations may be affected by the inter-assay variability of the EPO level within any individual. This study clearly showed, however, distinct patterns of relations between EPO and Hb levels according to whether mGFR was < or ≥ 30 mL/min/1.73 m 2 . This interaction suggests that EPO plays a role in different phases of CKD anemia. Similarly, the association between EPO levels and the other factors we studied should be interpreted with caution. Nonetheless, the absence of interaction between these factors and mGFR, in contrast to Hb, suggests that these factors have a persistent impact on EPO level throughout the range of mGFR.
Altogether, our findings may shed some light on the surprising and disappointing results from recent ESA trials, particularly the Trial to Reduce Cardiovascular Events with Aranesp Therapy 5 conducted in diabetic CKD patients. The higher EPO production found in our study associated with diabetes with nephropathy types other than diabetic glomerulopathy may be a missing link. These patients may predominantly have a vascular nephropathy and have enhanced EPO levels, despite their similar anemia rates. 15 This finding suggests resistance to EPO, which has recently been linked to mortality. 42 ESA should thus be administered cautiously to patients with enhanced EPO concentration, as they may benefit less and experience more adverse effects. Endogenous EPO response to anemia may bring new perspectives in the assessment of the potential benefit of an ESA prescription.
In conclusion, CKD anemia is associated with an early relative EPO deficiency, that rises from 28 to 64% as renal function declines. In patients with mGFR greater than 30 mL/min/1.73m², presence of anemia calls for explicative factors other than EPO deficiency, while it is probably the main determinant of anemia in patients with advanced CKD. But several factors besides Hb may stimulate EPO synthesis, bringing a more complex view of EPO response to Hb decrease in CKD population.
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